CN112190665A - Eye patch for relieving visual fatigue and preparation method thereof - Google Patents
Eye patch for relieving visual fatigue and preparation method thereof Download PDFInfo
- Publication number
- CN112190665A CN112190665A CN202011294765.2A CN202011294765A CN112190665A CN 112190665 A CN112190665 A CN 112190665A CN 202011294765 A CN202011294765 A CN 202011294765A CN 112190665 A CN112190665 A CN 112190665A
- Authority
- CN
- China
- Prior art keywords
- parts
- eye patch
- extraction
- heating
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims abstract description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 20
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 20
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940116229 borneol Drugs 0.000 claims abstract description 20
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 20
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940041616 menthol Drugs 0.000 claims abstract description 20
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 18
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 18
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 18
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 18
- 229960004853 betadex Drugs 0.000 claims abstract description 18
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims abstract description 16
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 13
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940087068 glyceryl caprylate Drugs 0.000 claims abstract description 12
- 238000000605 extraction Methods 0.000 claims description 71
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 32
- 238000010438 heat treatment Methods 0.000 claims description 29
- 238000012216 screening Methods 0.000 claims description 22
- 206010004542 Bezoar Diseases 0.000 claims description 18
- 244000020518 Carthamus tinctorius Species 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 238000005303 weighing Methods 0.000 claims description 18
- 244000146462 Centella asiatica Species 0.000 claims description 17
- 235000004032 Centella asiatica Nutrition 0.000 claims description 17
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 17
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 17
- 241000201295 Euphrasia Species 0.000 claims description 17
- 241000112528 Ligusticum striatum Species 0.000 claims description 17
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 241001313857 Bletilla striata Species 0.000 claims description 16
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 229920001285 xanthan gum Polymers 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 241000037740 Coptis chinensis Species 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 239000004744 fabric Substances 0.000 claims description 12
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 11
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims description 11
- 244000132619 red sage Species 0.000 claims description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 10
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000009835 boiling Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 241000972673 Phellodendron amurense Species 0.000 claims description 7
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 7
- 229920000570 polyether Polymers 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 240000004638 Dendrobium nobile Species 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 241000218202 Coptis Species 0.000 claims description 5
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 5
- 240000007164 Salvia officinalis Species 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 239000000084 colloidal system Substances 0.000 claims description 5
- 230000008093 supporting effect Effects 0.000 claims description 5
- 241001523681 Dendrobium Species 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000005412 red sage Nutrition 0.000 claims description 4
- 244000301850 Cupressus sempervirens Species 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- -1 caprylyl hydroxamic Chemical compound 0.000 claims description 2
- 239000000287 crude extract Substances 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 244000234609 Portulaca oleracea Species 0.000 claims 5
- 238000001556 precipitation Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 35
- 239000000463 material Substances 0.000 abstract description 24
- 230000001976 improved effect Effects 0.000 abstract description 13
- 229930003935 flavonoid Natural products 0.000 abstract description 4
- 150000002215 flavonoids Chemical class 0.000 abstract description 4
- 235000017173 flavonoids Nutrition 0.000 abstract description 4
- 229930182470 glycoside Natural products 0.000 abstract description 4
- 150000002338 glycosides Chemical class 0.000 abstract description 4
- 230000003260 anti-sepsis Effects 0.000 abstract description 3
- 239000006185 dispersion Substances 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 20
- 241000219304 Portulacaceae Species 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 6
- 238000007599 discharging Methods 0.000 description 6
- 230000004310 photopic vision Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000972672 Phellodendron Species 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 239000011229 interlayer Substances 0.000 description 5
- 230000002688 persistence Effects 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 239000002893 slag Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 208000024248 Vascular System injury Diseases 0.000 description 3
- 208000012339 Vascular injury Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 241001555026 Euphorbia humifusa Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000842539 Rhagades Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002740 effect on eyes Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940064064 purslane extract Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an eye patch, in particular to an eye patch for relieving visual fatigue and a preparation method thereof, wherein extracted traditional Chinese medicinal materials comprise glycosides and flavonoids which can be dissolved in ethanol, so that the eye patch has good dispersion effect, is convenient to extract and high in yield, beta-cyclodextrin, natural borneol, menthol and artificial musk are jointly prepared into an inclusion compound, the solubility of the components can be improved, the stability is enhanced, p-hydroxyacetophenone, glyceryl caprylate, caprylic hydroxamic acid and 1, 2-hexanediol are used as auxiliary materials of the product, the main effects of antisepsis and moisture preservation are achieved, the viscosity can be improved, a continuous film can be formed, the adhesion force with an eye pad can be improved, and the eye patch for relieving visual fatigue is finally obtained.
Description
Technical Field
The invention relates to an eye patch, in particular to an eye patch for relieving visual fatigue and a preparation method thereof.
Background
Due to the continuous increase of living pressure, the working strength of people is higher and higher, electronic products in contact with the electronic products are more and more, the eyes of people are used excessively, the eyes are tired, the vision is degraded, even the eyes are diseased, and the normal work and life of people are influenced.
In order to solve the problem of eyes, people research various products and methods for eye treatment and physical therapy, such as eye massage exercises, eye massage instruments, eye drops, eye patches, radiation-proof glasses, eyesight improving paste, eyesight improving oral liquid, goggles and the like, and the products are various in types and have obvious effects.
The eye mask is a commonly used eye protection product in the existing products, has low cost and long storage time, can carry a large amount of essence, has good moistening effect on eyes and skin around the eyes, and can improve the using effect especially by adding an auxiliary agent with permeation and anti-inflammation effects.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides an eye patch for relieving asthenopia and a preparation method thereof, wherein the eye patch is reasonable in formula and can effectively relieve asthenopia.
The invention is realized by the following technical scheme: an eye patch for relieving asthenopia comprises, by weight, 300-500 parts of wild chrysanthemum flower, 200-400 parts of salvia miltiorrhiza, 100-200 parts of coptis chinensis, 50-100 parts of ligusticum wallichii, 50-100 parts of bletilla striata, 20-100 parts of purslane, 60-120 parts of centella asiatica, 60-120 parts of eyebright, 50-150 parts of phellodendron, 50-100 parts of safflower, 60-120 parts of cassia seed, 50-200 parts of dendrobe, 1-5 parts of artificial musk, 5-10 parts of artificial bezoar, 1-5 parts of natural borneol, 2-8 parts of menthol, 20-50 parts of pearl powder, 7-25 parts of beta-cyclodextrin, 5-20 parts of propylene glycol, 1-10 parts of p-hydroxyacetophenone, 0.5-1 part of glyceryl caprylate, 261-5 parts of glyceryl polyether, 0.5-2 parts of xanthan gum, 0.5-1 part of caprylyl hydroximic acid and 0.5-1 part of 1, 2-hexanediol.
Further, the medicine comprises, by weight, 400-500 parts of wild chrysanthemum flower, 320-400 parts of salvia miltiorrhiza, 130-200 parts of coptis chinensis, 50-80 parts of ligusticum wallichii, 70-100 parts of bletilla striata, 40-60 parts of purslane, 80-100 parts of centella asiatica, 90-100 parts of eyebright, 50-100 parts of phellodendron, 50-80 parts of safflower, 80-100 parts of cassia seed, 50-100 parts of dendrobium, 1-4 parts of artificial musk, 7-10 parts of artificial bezoar, 2-3 parts of natural borneol, 2-5 parts of menthol, 30-50 parts of pearl powder, 9-21 parts of beta-cyclodextrin, 12-20 parts of propylene glycol, 5-10 parts of p-hydroxyacetophenone, 0.8-1 part of glyceryl caprylate, 263-5 parts of glyceryl polyether, 0.8-1 part of xanthan gum, 0.7-1 part of caprylyl hydroxamic acid, 0.7-1 part of 1, 2-hexanediol.
Further, the traditional Chinese medicine composition comprises, by weight, 400 parts of wild chrysanthemum flower, 330 parts of salvia miltiorrhiza, 150 parts of coptis chinensis, 80 parts of ligusticum wallichii, 80 parts of bletilla striata, 45 parts of purslane, 100 parts of centella, 100 parts of eyebright, 100 parts of cortex phellodendri, 60 parts of safflower, 100 parts of semen cassiae, 80 parts of dendrobe, 2 parts of artificial musk, 8 parts of artificial bezoar, 2 parts of natural borneol, 3 parts of menthol, 30 parts of pearl powder, 15 parts of beta-cyclodextrin, 15 parts of propylene glycol, 5 parts of p-hydroxyacetophenone, 1 part of glyceryl caprylate, 1 part of glyceryl polyether-263, 1 part of xanthan gum, 1 part of caprylyl hydroximic acid and 1 part of 1, 2-hexanediol.
A preparation method of an eye patch for relieving asthenopia comprises the following steps,
step one, preparing an extracting solution, namely weighing wild chrysanthemum flower, red sage root, coptis root, ligusticum wallichii, bletilla striata, purslane, centella asiatica, eyebright, golden cypress, safflower carthamus, cassia seed and dendrobium, adding 7-10 times of water, heating to boil, stopping heating, stirring, heating to slightly boil, continuing for 2-3h, and sieving by using a 80-mesh sieve to obtain the extracting solution for later use;
step two, preparing an inclusion compound, namely weighing natural borneol and menthol, then adding the natural borneol and the menthol into ethanol for dissolving to obtain a first mixture, then weighing beta-cyclodextrin and propylene glycol, adding the beta-cyclodextrin and the propylene glycol into water to obtain a second mixture, adding the second mixture into a colloid mill, starting grinding, then adding the first mixture, and continuously grinding to obtain the inclusion compound for later use;
step three, preparing the composition, weighing p-hydroxyacetophenone, adding the p-hydroxyacetophenone into propylene glycol, heating to 45-55 ℃, stirring to obtain a third mixture, mixing the artificial bezoar and the pearl powder with the extracting solution, sequentially adding the glycerol polyether 26 and the xanthan gum, heating to 45-55 ℃, adding the inclusion compound, then adding the glycerol caprylate, the caprylyl hydroximic acid, the 1, 2-hexanediol, the third mixture and the pure water, stirring, filtering to obtain the composition,
and step four, preparing the eye patch, namely adding the composition onto an eye pad, sterilizing and packaging to obtain the eye patch.
Further, the first step includes the steps of,
step A, weighing wild chrysanthemum, salvia miltiorrhiza, coptis chinensis, ligusticum wallichii, bletilla striata, purslane, centella asiatica, eyebright, phellodendron amurense, safflower, cassia seed and dendrobium nobile, putting into a first extraction tank, adding 8 times of water, heating to boil, stirring for 15 minutes, heating to boil again, timing, keeping slight boiling for 2 hours, and sieving by a 80-mesh sieve to obtain a first extraction solution;
step B, putting filter residues into a second extraction tank, adding 6 times of hot water with the temperature of 60 ℃, heating to boil, keeping slight boiling for 1.5h, sieving by a 80-mesh sieve to obtain a second extraction solution, and combining the first extraction solution and the second extraction solution to obtain a crude extraction solution;
and step C, separating the crude extract by a centrifugal machine, sterilizing to obtain an extract, and refrigerating at the temperature of-3-4 ℃ for later use.
Further, step one is gone on in drawing equipment in succession, draw equipment in succession includes the frame, the frame upper end is provided with and draws jar one, it is provided with and draws jar two to draw a jar downside, it is provided with discharging pipe one to draw a jar lower extreme and draw between jar two, it is provided with discharging pipe two to draw jar two lower extremes, discharging pipe one and two top-down of discharging pipe have set gradually barrier valve, discharge valve, be provided with the screening plant that can overturn between barrier valve and the discharge valve, screening plant's screening granularity is 80 meshes, be provided with the drain pipe between discharge valve and the screening plant, two drain pipes communicate to the gunbarrel, the gunbarrel is connected to centrifuge.
Further, screening plant includes the disk seat, be provided with rotatory frame in the disk seat, rotatory frame upper end is provided with the support grid tray, support grid tray up end is provided with the filter cloth, the filter cloth is 80 mesh filter cloth, the filter cloth edge is provided with the clamping ring, the clamping ring can be dismantled with rotatory frame and be connected.
The invention has the beneficial effects that: an eye patch for relieving asthenopia,
flos Chrysanthemi Indici has heat and toxic materials clearing away effect, and can be used for treating conjunctival congestion, swelling and pain, headache, and giddiness;
the radix Salviae Miltiorrhizae has effects of promoting blood circulation, regulating menstruation, removing blood stasis, relieving pain, cooling blood, resolving carbuncle, relieving restlessness, and tranquilizing mind;
cortex Phellodendri has effects of clearing heat, eliminating dampness, purging pathogenic fire, removing steam, removing toxic substance, and treating sore;
coptis root, rhizoma Coptidis, having the actions of clearing heat and drying dampness, purging fire and removing toxicity, can be used for treating conjunctival congestion and aphtha;
the ligusticum wallichii has the effects of activating blood and promoting qi, dispelling wind and relieving pain, is good for treating various symptoms of blood stasis and qi stagnation, can improve the blood circulation of skin and activate skin cells, has the effect of delaying skin aging, and can achieve the aims of retaining youthful looks and brightening the skin and lubricating and brightening the skin when being prepared into skin cosmetics;
bletilla has the efficacies of astringency and hemostasis, detumescence and tissue regeneration promotion, and can also detumescence and tissue regeneration promotion, and is commonly used for sores, rhagades of hands and feet, and burns caused by water and fire;
the purslane has the effects of clearing away heat and toxic materials, cooling blood and relieving swelling, is usually externally used for treating various skin diseases, and modern researches find that the purslane extract has the effects of resisting infection, allergy, oxidation and aging;
centella asiatica has the effects of clearing heat and promoting diuresis, and detoxifying and reducing swelling, and is used for damp-heat jaundice, carbuncle swelling and sore toxicity, and traumatic injury;
the eyebright has the effects of clearing away heat and toxic materials, and treating the primary heat diseases such as thirst, headache, cough due to lung heat and sore throat;
semen Cassiae has effects of clearing heat and detoxicating, improving eyesight and removing nebula, and relieving conjunctival congestion and swelling pain, and is added into eye patches for middle-aged and elderly people and teenagers respectively;
herba Dendrobii has effects of resisting oxidation, relieving eye dryness, fatigue, photophobia, and resisting inflammation, contains abundant mucus, and has nourishing and moistening effects on human skin;
safflower, having the functions of promoting blood circulation, removing blood stasis and relieving pain, contains active substances capable of improving and promoting skin microcirculation;
the artificial musk is extremely fragrant in smell, extremely strong in fleeing property and extremely strong in resuscitation inducing, blocking and refreshing effects, can be applied to eyes for resisting inflammation and bacteria and promoting the growth of corneal epithelial cells and fibroblasts, and has similar component effects as a musk substitute;
the artificial bezoar has the effects of clearing away heat and toxic materials, and modern pharmacological studies prove that the bezoar has the effects of resisting bacteria, diminishing inflammation, clearing away heat and toxic materials and resisting viruses, and the artificial bezoar has similar component effects as a bezoar substitute;
the pearl powder has the effects of calming the nerves, arresting convulsion, improving eyesight, removing nebula, detoxifying, promoting granulation and the like;
natural borneol and menthol can promote the percutaneous absorption of the medicine, and has the effects of resisting bacteria and inflammation, inducing resuscitation, relieving pain and tranquilizing;
beta-cyclodextrin, natural borneol, menthol and artificial musk are prepared into the inclusion compound together, so that the solubility of the components can be improved, and the stability can be enhanced;
the propylene glycol, the glyceryl polyether-26 and the xanthan gum are used as auxiliary materials of the product, so that the product can keep moisture, thicken and adjust dressing feeling;
the product auxiliary materials comprise p-hydroxyacetophenone, glyceryl caprylate, caprylyl hydroximic acid and 1, 2-hexanediol, and the main effects are antisepsis and moisture preservation.
In the extracted traditional Chinese medicinal materials, main components are glycosides and flavonoids, the glycosides and the flavonoids can be dissolved in ethanol, the dispersion effect is good, the extraction is convenient, the yield is high, the beta-cyclodextrin, the inclusion compound prepared together with natural borneol, menthol and artificial musk can improve the component solubility and enhance the stability, the hydroxyacetophenone, the glyceryl caprylate, the caprylyl hydroximic acid and the 1, 2-hexanediol are used as product auxiliary materials, the main effects of antisepsis and moisture preservation can be realized, the viscosity can be improved, a continuous film can be formed, the adhesion force with an eye pad can be improved, and the eye patch for relieving the visual fatigue is finally obtained.
Drawings
FIG. 1 is a schematic view of a continuous extraction apparatus;
FIG. 2 is a schematic front view of a tapping pipe;
FIG. 3 is a schematic front cross-sectional view of a screening device;
FIG. 4 is an enlarged view of a portion of FIG. 3A;
FIG. 5 is a schematic view of a structure of a press ring and a bolt;
FIG. 6 is a schematic front view of a settling tank;
FIG. 7 is a schematic top view of a settling tank;
FIG. 8 is a schematic view of a clathrate production apparatus;
FIG. 9 is a schematic view of a composition preparing apparatus;
wherein: 1-frame, 2-first extraction tank, 3-second extraction tank, 4-first discharge pipe, 5-second discharge pipe, 6-slag disk, 7-blocking valve, 8-sieving device, 9-connecting plate, 10-liquid outlet pipe, 11-discharge valve, 12-settling tank, 13-metering pump, 14-tubular centrifuge, 15-valve seat, 16-rotating frame, 17-supporting grid plate, 18-pressing ring, 19-filter cloth, 20-main shaft, 21-bearing, 22-annular pipe, 23-manifold, 24-first reaction kettle, 25-second reaction kettle, 26-colloid mill, 27-third extraction tank, 28-third discharge pipe, 29-bolt, 30-heating pipe, 31-stirring motor and 32-interlayer.
Detailed Description
In the description of the present invention, it should also be noted that, unless otherwise explicitly specified or limited, the terms "disposed," "mounted," "connected," and "connected" are to be construed broadly and may, for example, be fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meanings of the above terms in the present invention can be understood in specific cases to those skilled in the art.
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the following embodiments, the moisture content of the wild chrysanthemum flower, the red sage root, the coptis root, the ligusticum wallichii, the bletilla striata, the purslane, the centella asiatica, the eyebright, the phellodendron amurense, the safflower, the cassia seed and the dendrobium nobile is lower than 15%, the crushing is convenient, the particle size is 1cm, the extraction efficiency can be ensured, the sugar dissolution caused by the fracture of section cells can be reduced, and the extraction effect can be ensured.
The artificial musk, the artificial bezoar, the natural borneol, the menthol and the pearl powder are crushed into 400 meshes, and the dispersion effect is good.
The first step is carried out in continuous extraction equipment which is shown in figures 1-7 and comprises a rack 1, wherein the rack is a steel structure frame and is high in structural stability and 3m in height, an extraction tank I2 is installed at the upper end of the rack, an extraction tank II 3 is installed at the lower side of the extraction tank I, a discharge pipe I4 is communicated between the lower end of the extraction tank I and the extraction tank II, a discharge pipe II 5 is installed at the lower end of the extraction tank II, the extraction tank I and the extraction tank II are both interlayer extraction tanks and comprise tank bodies, an interlayer 32 is sleeved on the outer wall of the lower end of each tank body, a heating pipe 30 is arranged in the interlayer, the heating pipe can be a spiral air pipe and can be an electric heating pipe through oil or steam heating, a part without the interlayer is coated with a heat insulation coating, a stirring motor 31 is installed at the upper end of the extraction tank I, can improve the extraction effect, the feed inlet of extracting jar one is installed in one side of agitator motor, extract jar one, extract jar two and all install the relief valve, the manometer, the trachea, the relief valve is used for avoiding extracting jar atmospheric pressure transfinite, the manometer is used for monitoring atmospheric pressure, the trachea is used for communicating the air pump, and then pressure boost or decompression, can also communicate to oxygen, nitrogen gas etc., the water inlet of extracting jar one and extracting jar two all sets up in the lower part of the jar body, improve the mixed effect in the process of water injection, discharging pipe one and discharging pipe two are installed in proper order from top to bottom and are blocked valve 7, blow-off valve 11, block valve and blow-off valve are the automatically controlled butterfly valve, the screening plant that can overturn is installed between block valve and the blow-off valve, the screening granularity of screening plant is 80 meshes, specifically, screening plant includes disk seat 15, install revolving frame 16 in, the two sections are connected through a connecting plate 9, the corresponding connecting plate is positioned through a positioning pin to ensure the installation precision, a sealing ring matched with the rotating frame is arranged in the valve seat, the cross section of the inner end surface of the sealing ring is arc-shaped, the outer end surface of the rotating frame is also arc-shaped, the sealing effect between the rotating frame and the sealing ring can be improved, the structural strength of the rotating frame can also be improved, one end of the rotating frame is connected with a short shaft, the short shaft is inserted into the corresponding sealing ring and is supported through a bearing, the other end of the rotating frame is connected with a main shaft 20, the main shaft extends outwards to the outside of the valve seat and is connected with a driving motor, the driving motor is a stepping motor and can control the rotating angle of the rotating frame, the main shaft is connected with the valve seat through the bearing to ensure the rotating stability, a supporting, the upper end face of the supporting grid plate is paved with filter cloth 19 which is 80 meshes of filter cloth, the edge of the filter cloth is provided with a press ring 18 which is detachably connected with the rotary frame, the inner side of the press ring is pressed on the upper side of the supporting grid plate, the outer side of the press ring is connected with the rotary frame through 6-8 bolts 29 which are uniformly distributed, 6-8 outward openings are uniformly processed on the outer side of the press ring for preventing the bolts from being separated, the outer diameter of the upper ends of the bolts is smaller than the outer diameter of the thread and matched with the openings, the bolts can be clamped at the openings and can not be separated even if loosened, further the safety of subsequent processing is ensured, a liquid outlet pipe 10 is arranged between the discharge valve and the screening device, the two liquid outlet pipes are communicated with the sedimentation tank 12, specifically, the two liquid outlet pipes are connected with a main pipe, the main pipe is communicated with the lower end of the sedimentation tank through an annular pipe, preliminary sediment can be carried out through the gunbarrel, for subsequent centrifugal separation makes preparation, can cool down simultaneously, the injection of many manifolds can make the interior material of gunbarrel even, the cooling effect is better, avoids damaging centrifuge, the gunbarrel passes through the measuring pump and is connected to centrifuge, centrifuge is tubular centrifuge 14, the rotational speed is 3000 rpm.
Through this equipment of drawing in succession, throw the material in drawing jar one, close corresponding valve that blocks, throw material, water injection, heating, stirring, block the valve and open after accomplishing, sieve through screening plant, the extract passes through the drain pipe and discharges to the gunbarrel, opens the relief valve, then rotatory revolving frame is to vertical, and the slag charge falls into and draws jar two in, can realize drawing in succession, and can guarantee the temperature of slag charge, reduce cost.
A slag pan 6 is arranged below the second extraction tank and used for collecting slag.
And step two is carried out in an inclusion compound preparation device, as shown in fig. 8, the inclusion compound preparation device comprises a first reaction kettle 24 and a second reaction kettle 25, both the first reaction kettle and the second reaction kettle are stirring type reaction kettles, the natural borneol and the menthol are dissolved in the first reaction kettle, the beta-cyclodextrin and the propylene glycol are dissolved in the second reaction kettle, and the first reaction kettle and the second reaction kettle are communicated to a colloid mill 26, so that the control is convenient, the manual intervention is reduced, and the pollution is reduced.
Step three is carried out in the composition preparation device, as shown in fig. 9, the composition preparation device comprises an extraction tank III 27, the extraction tank III and the extraction tank have the same structure, a discharge pipe III 28 is installed at the lower end of the extraction tank III, a blocking valve and a discharge valve are sequentially arranged on the discharge pipe III from top to bottom, a reversible screening device is arranged between the blocking valve and the discharge valve, the screening granularity of the screening device is 80 meshes, and a discharge pipe is arranged between the discharge valve and the screening device, so that mixing and screening can be carried out.
In the following embodiments, the method for preparing an eye patch for relieving asthenopia comprises the following steps,
step one, preparing an extracting solution, namely weighing wild chrysanthemum flower, red sage root, coptis root, ligusticum wallichii, bletilla striata, purslane, centella asiatica, eyebright, golden cypress, safflower carthamus, cassia seed and dendrobium, adding 8 times of water, heating until boiling, stopping heating, stirring, heating until slight boiling, controlling the temperature to be 100 ℃, continuing for 2 hours, and sieving by a 80-mesh sieve to obtain the extracting solution for later use;
step two, preparing an inclusion compound, namely weighing natural borneol and menthol, then adding 3 times of ethanol for dissolving, wherein the ethanol is 95% ethanol, stirring in the dissolving process at the stirring speed of 200rpm to obtain a first mixture, then weighing beta-cyclodextrin and propylene glycol, adding 5 times of water to obtain a second mixture, adding the second mixture into a colloid mill, starting grinding for 2min, then adding the first mixture, and continuing grinding for 5min to obtain the inclusion compound for later use;
step three, preparing a composition, namely weighing p-hydroxyacetophenone, adding the p-hydroxyacetophenone into 2 times of propylene glycol, heating to 50 ℃, stirring to obtain a third mixture, mixing artificial bezoar and pearl powder with an extracting solution, sequentially adding glycerol polyether 26 and xanthan gum, heating to 50 ℃, adding an inclusion compound, then adding glycerol caprylate, caprylyl hydroximic acid, 1, 2-hexanediol, the third mixture and pure water, stirring, and filtering to obtain the composition, wherein in the step, the pearl powder and the artificial bezoar are mixed with the extracting solution after 0.5 times of water is added, and the dispersing effect is good;
and step four, preparing the eye patch, namely adding the composition onto the eye pad through an automatic filling machine, sterilizing and packaging to obtain the eye patch, wherein the eye patch is high in automation degree, low in labor intensity and good in sanitation effect.
In order to make full use of the method, the first step comprises the following steps,
step A, weighing wild chrysanthemum, salvia miltiorrhiza, coptis chinensis, ligusticum wallichii, bletilla striata, purslane, centella asiatica, eyebright, phellodendron amurense, safflower, cassia seed and dendrobium nobile, putting into a first extraction tank, adding 8 times of water, heating to boil, stirring for 15 minutes, heating to boil again, timing, keeping slight boiling for 2 hours, and sieving by a 80-mesh sieve to obtain a first extraction solution;
step B, putting filter residues into a second extraction tank, adding 6 times of hot water with the temperature of 60 ℃, heating to boil, keeping slight boiling for 1.5h, sieving by a 80-mesh sieve to obtain a second extraction solution, and combining the first extraction solution and the second extraction solution to obtain a crude extraction solution;
and step C, separating the crude liquid of the extracting solution by a centrifugal machine, wherein the centrifugal machine is a tubular centrifugal machine, the rotating speed is 3000rpm, sterilizing to obtain the extracting solution, and refrigerating at the temperature of-3-4 ℃ for later use.
To determine the optimal extraction parameters, orthogonal experiments are to be used to optimize the conditions involved in the extraction process, typically: the extraction frequency, the decoction time and the water addition amount have obvious influence on the extraction result, so that the extraction frequency, the decoction time and the water addition amount are taken as influence factors, three levels are respectively selected, and the medicinal materials of the water decoction part are not very hard, so that the medicinal materials can be soaked for about two hours to be thoroughly transparent, 3 times of extraction are selected as the maximum times in the aspect of extraction frequency, and 1 time, 2 times and 3 times of extraction are taken as the levels of the extraction frequency; the texture of the medicinal materials simultaneously determines that the decoction time should not be too long, so that the common 2 hours are taken as the maximum extraction time; because the water absorption of the traditional Chinese medicinal materials in the formula is about 1.5 times, the traditional Chinese medicinal materials in the formula are dense except the wild chrysanthemum flower, the safflower, the centella asiatica and the eyebright, therefore, 10 times of water is selected as the maximum water addition amount, the medicinal materials can be completely submerged when water is added to about 4 times of water, 6 times of water absorption is selected as the minimum water addition amount, and the water addition level is determined as follows: 6 times, 8 times and 10 times. The test was arranged on the table L9(34) and the best extraction process conditions were screened. The factor levels are shown in table one.
Table-factor level table
Determination of evaluation indexes: the main active ingredients of the 12 medicinal materials in the formula are glycosides and flavonoids, which can be dissolved in ethanol, so that an ethanol extract is used as an important index for research of an extraction process, and the weight coefficient is determined to be 0.7; the amount of the paste can be indirectly measured, and the weight coefficient is set to be 0.3. Therefore, the comprehensive score of the alcohol extract and the cream yield is selected as the evaluation index of the test.
The test method comprises the following steps: weighing 60g of the medicinal materials according to the formula amount, taking 9 parts of the medicinal materials, arranging the test according to the conditions corresponding to the test numbers in the orthogonal table, and collecting the extracting solution as a stock solution for later use.
③ the cream yield measuring method: concentrating the stock solutions into soft extract, oven drying at 60 deg.C, taking out, rapidly cooling in a drier, weighing, and calculating.
Fourthly, measuring the alcohol extract: taking a proper amount of dry extract powder under the extract yield term, precisely weighing, measuring according to a hot dipping method (appendix IX A of the first part of the Chinese pharmacopoeia 2010 edition) under the alcohol-soluble extract measuring method term, using 95% ethanol as a solvent, and calculating an alcohol extract.
The design and measurement results of the test are shown in the table II.
Watch II L9(34) Orthogonal test table
Analysis of variance
Table three variance analysis table
Note: f0.05(2,2)=19.0,F0.01(2,2)=99.0。
The analysis result of variance shows that the extraction times and the extraction time have significant difference on the influence of extracting effective components; the influence of the water addition amount is not great. Orthogonal experimental results show that the optimal extraction processes are A2B2C1 and A2B3C 1. Considering the water absorption rate and extraction time of the medicinal materials, the first extraction time is set to be 2 hours, and the second extraction time is set to be 1.5 hours. Namely: the first time is added with 8 times of water for 2.0 hours, and the second time is added with 6 times of water for 1.5 hours.
Example 1
An eye patch for relieving asthenopia comprises, by weight, 4000g of wild chrysanthemum flower, 3000g of salvia miltiorrhiza, 1500g of coptis chinensis, 800g of ligusticum wallichii, 800g of bletilla striata, 450g of purslane, 1000g of centella asiatica, 1000g of euphorbia humifusa, 1000g of phellodendron, 600g of safflower, 1000g of semen cassiae, 800g of dendrobe, 20g of artificial musk, 50g of artificial bezoar, 10g of natural borneol, 30g of menthol, 300g of pearl powder, 150g of beta-cyclodextrin, 150g of propylene glycol, 50g of p-hydroxyacetophenone, 10g of glyceryl caprylate, 2630 g of glyceryl polyether-2630 g, 10g of xanthan gum, 10g of caprylyl hydroximic acid and 10g of 1, 2-hexanediol.
Example 2
An eye patch for relieving asthenopia comprises, by weight, 3000g of wild chrysanthemum flower, 2000g of salvia miltiorrhiza, 1000g of coptis chinensis, 500g of ligusticum wallichii, 500g of bletilla striata, 300g of purslane, 800g of centella asiatica, 800g of eyebright herb, 500g of phellodendron, 500g of safflower, 800g of semen cassiae, 500g of dendrobe, 50g of artificial musk, 100g of artificial bezoar, 15g of natural borneol, 30g of menthol, 200g of pearl powder, 80g of beta-cyclodextrin, 9g of propylene glycol, 3g of p-hydroxyacetophenone, 5g of glyceryl caprylate, 5g of glyceryl polyether-2620 g, 5g of xanthan gum, 10g of caprylyl hydroximic acid and 10g of 1, 2-hexanediol.
Example 3
An eye patch for relieving asthenopia comprises the following raw materials, by weight, 5000g of wild chrysanthemum flower, 4000g of red-rooted salvia root, 2000g of coptis chinensis, 1000g of ligusticum wallichii, 800g of bletilla striata, 600g of purslane, 1200g of centella asiatica, 1200g of eyebright, 1500g of phellodendron, 1000g of safflower, 1200g of semen cassiae, 1500g of dendrobe, 30g of artificial musk, 80g of artificial bezoar, 5g of natural borneol, 20g of menthol, 400g of pearl powder, 200g of beta-cyclodextrin, 200g of propylene glycol, 80g of p-hydroxyacetophenone, 10g of glyceryl caprylate, 2630 g of glyceryl polyether-2630 g, 10g of xanthan gum, 10g of caprylyl hydroximic acid and 10g of 1, 2-.
Examples 1 to 3 the eye patch test for relieving asthenopia obtained was as follows:
the three eye patches for relieving asthenopia are prepared respectively, and the irritation is detected by a CAMVA test. The abundant network of blood vessels on the chorioallantoic membrane (CAM) mimics the conjunctival structure of the eye well, and therefore CAM-based in vitro testing is one of the earliest and most widely used alternatives to ocular stimulation. The test utilizes the characteristics of complete, obvious and transparent chorioallantoic membrane vascular system of embryo-aged fertilized chicken embryos at the 10 th day of incubation, a certain amount of test substances are directly contacted with the chorioallantoic membrane, after a period of action, the vascular injuries (such as ghost blood vessels, capillary blood vessel congestion and hemorrhage with different degrees) of the chorioallantoic membrane are observed, the different vascular injury degrees are scored, and the more serious the vascular injury is, the larger the score is.
As a result of the test, the eggs did not show irritative symptoms.
2. Test for relieving asthenopia
Judging according to judgment standards in 'evaluation procedure and inspection method of health product functional science'. 40 volunteer subjects with long-term eye use and asthenopia are screened, 30 volunteer subjects are pasted with formulas 1,2 and 3 according to requirements, 10 volunteer subjects are blank, and after 10 days, the total integral of symptoms before and after the experimental group is compared.
The inspection basis is as follows: evaluation procedure and test method for functional science of health products
And (3) result and judgment:
after the eye patch of the formula 1 is used for 10 days, the total integral of the comparative symptoms before and after the test group of the formula 1 is reduced by 3.14, and the photopic vision persistence is increased by 22.3 percent; compared with a blank control group, the total integral of symptoms of the test group is reduced by 2.13, and the photopic vision persistence is increased by 20.01 percent; the total effective rate is obviously improved.
After the eye patch of the formula 2 is used for 10 days, the total integral of the comparative symptoms before and after the test group of the formula 2 is reduced by 2.8, and the photopic vision persistence is improved by 18.40 percent; compared with a blank control group, the total integral of symptoms of the test group is reduced by 2.04, and the photopic vision persistence is increased by 15.15%; the total effective rate is obviously improved.
After the eye patch of the formula 3 is used for 10 days, the total integral of the comparative symptoms before and after the test group of the formula 3 is reduced by 3.65 percent, and the photopic vision persistence is improved by 27.33 percent; compared with a blank control group, the total integral of symptoms of the test group is reduced by 2.44, and the photopic vision durability is increased by 25.29 percent; the total effective rate is obviously improved.
All indexes of the three formula experiments reach effective judgment standards, and have high significant difference (P is less than 0.01) through self-pairing t test and composition t test comparison: other health related indicators of the subjects did not change significantly before and after the test. The judgment was carried out according to the judgment standards in "evaluation procedure and test method for functional science of health products" (DB 22-T397-2004): the eye patch for relieving asthenopia disclosed by the invention has the function of relieving asthenopia.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications may be made to the embodiments or portions thereof without departing from the spirit and scope of the invention.
Claims (7)
1. An eye patch for relieving asthenopia is characterized by comprising, by weight, 300-500 parts of wild chrysanthemum flower, 200-400 parts of salvia miltiorrhiza, 100-200 parts of coptis chinensis, 50-100 parts of ligusticum wallichii, 50-100 parts of bletilla striata, 20-100 parts of purslane, 60-120 parts of centella asiatica, 60-120 parts of eyebright, 50-150 parts of phellodendron amurense, 50-100 parts of safflower, 60-120 parts of semen cassiae, 50-200 parts of dendrobe, 1-5 parts of artificial musk, 5-10 parts of artificial bezoar, 1-5 parts of natural borneol, 2-8 parts of menthol, 20-50 parts of pearl powder, 7-25 parts of beta-cyclodextrin, 5-20 parts of propylene glycol, 1-10 parts of p-hydroxyacetophenone, 0.5-1 part of glyceryl caprylate, 261-5 parts of glyceryl polyether, 5 parts of, 0.5-2 parts of xanthan gum, 0.5-1 part of caprylyl hydroximic acid and 0.5-1 part of 1, 2-hexanediol.
2. An eye patch for relieving asthenopia is characterized by comprising, by weight, 400-500 parts of wild chrysanthemum flower, 320-400 parts of salvia miltiorrhiza, 130-200 parts of coptis chinensis, 50-80 parts of ligusticum wallichii, 70-100 parts of bletilla striata, 40-60 parts of purslane, 80-100 parts of centella asiatica, 90-100 parts of eyebright, 50-100 parts of phellodendron amurense, 50-80 parts of safflower, 80-100 parts of semen cassiae, 50-100 parts of dendrobium nobile, 1-4 parts of artificial musk, 7-10 parts of artificial bezoar, 2-3 parts of natural borneol, 2-5 parts of menthol, 30-50 parts of pearl powder, 9-21 parts of beta-cyclodextrin, 12-20 parts of propylene glycol, 5-10 parts of p-hydroxyacetophenone, 0.8-1 part of glyceryl caprylate, 263-5 parts of glyceryl polyether, 263-5 parts of pearl powder, and the like, 0.8-1 part of xanthan gum, 0.7-1 part of caprylyl hydroximic acid and 0.7-1 part of 1, 2-hexanediol.
3. The eye patch for relieving asthenopia according to claim 1, which comprises, by weight, 400 parts of wild chrysanthemum flower, 330 parts of salvia miltiorrhiza, 150 parts of coptis chinensis, 80 parts of ligusticum wallichii, 80 parts of bletilla striata, 45 parts of purslane, 100 parts of centella asiatica, 100 parts of eyebright herb, 100 parts of phellodendron amurense, 60 parts of safflower carthamus, 100 parts of cassia seed, 80 parts of dendrobium nobile, 2 parts of artificial musk, 8 parts of artificial bezoar, 2 parts of natural borneol, 3 parts of menthol, 30 parts of pearl powder, 15 parts of beta-cyclodextrin, 15 parts of propylene glycol, 5 parts of p-hydroxyacetophenone, 1 part of glyceryl caprylate, 1 part of glyceryl polyether-263, 1 part of xanthan gum, 1 part of caprylyl hydroxamic acid and 1 part of 1, 2-hexanediol.
4. A method of producing the eye patch for alleviating asthenopia according to claim 1, which comprises the steps of,
step one, preparing an extracting solution, namely weighing wild chrysanthemum flower, red sage root, coptis root, ligusticum wallichii, bletilla striata, purslane, centella asiatica, eyebright, golden cypress, safflower carthamus, cassia seed and dendrobium, adding 7-10 times of water, heating to boil, stopping heating, stirring, heating to slightly boil, continuing for 2-3h, and sieving by using a 80-mesh sieve to obtain the extracting solution for later use;
step two, preparing an inclusion compound, namely weighing natural borneol and menthol, then adding the natural borneol and the menthol into ethanol for dissolving to obtain a first mixture, then weighing beta-cyclodextrin and propylene glycol, adding the beta-cyclodextrin and the propylene glycol into water to obtain a second mixture, adding the second mixture into a colloid mill, starting grinding, then adding the first mixture, and continuously grinding to obtain the inclusion compound for later use;
step three, preparing the composition, weighing p-hydroxyacetophenone, adding the p-hydroxyacetophenone into propylene glycol, heating to 45-55 ℃, stirring to obtain a third mixture, mixing the artificial bezoar and the pearl powder with the extracting solution, sequentially adding the glycerol polyether 26 and the xanthan gum, heating to 45-55 ℃, adding the inclusion compound, then adding the AT-01, the third mixture and the pure water, stirring, filtering to obtain the composition,
and step four, preparing the eye patch, namely adding the composition onto an eye pad, sterilizing and packaging to obtain the eye patch.
5. The method for preparing an eye patch for relieving asthenopia according to claim 4, wherein the first step comprises the steps of,
step A, weighing wild chrysanthemum, salvia miltiorrhiza, coptis chinensis, ligusticum wallichii, bletilla striata, purslane, centella asiatica, eyebright, phellodendron amurense, safflower, cassia seed and dendrobium nobile, putting into a first extraction tank, adding 8 times of water, heating to boil, stirring for 15 minutes, heating to boil again, timing, keeping slight boiling for 2 hours, and sieving by a 80-mesh sieve to obtain a first extraction solution;
step B, putting filter residues into a second extraction tank, adding 6 times of hot water with the temperature of 60 ℃, heating to boil, keeping slight boiling for 1.5h, sieving by a 80-mesh sieve to obtain a second extraction solution, and combining the first extraction solution and the second extraction solution to obtain a crude extraction solution;
and step C, separating the crude extract by a centrifugal machine, sterilizing to obtain an extract, and refrigerating at the temperature of-3-4 ℃ for later use.
6. The method for preparing an eye patch for relieving visual fatigue as claimed in claim 5, wherein the first step is performed in a continuous extraction device, the continuous extraction device comprises a frame, a first extraction tank is arranged at the upper end of the frame, a second extraction tank is arranged at the lower side of the first extraction tank, a first discharge pipe is arranged between the lower end of the first extraction tank and the second extraction tank, a second discharge pipe is arranged at the lower end of the second extraction tank, a blocking valve and a discharge valve are sequentially arranged from top to bottom, a reversible screening device is arranged between the blocking valve and the discharge valve, the screening device has a screening granularity of 80 meshes, a liquid outlet pipe is arranged between the discharge valve and the screening device, the two liquid outlet pipes are communicated to a precipitation tank, and the precipitation tank is connected to a centrifuge.
7. The preparation method of the eye patch for relieving the visual fatigue as claimed in claim 6, wherein the screening device comprises a valve seat, a rotating frame is arranged in the valve seat, a supporting grid plate is arranged at the upper end of the rotating frame, a filter cloth is arranged on the upper end face of the supporting grid plate, the filter cloth is an 80-mesh filter cloth, a pressing ring is arranged on the edge of the filter cloth, and the pressing ring is detachably connected with the rotating frame.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011294765.2A CN112190665A (en) | 2020-11-18 | 2020-11-18 | Eye patch for relieving visual fatigue and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011294765.2A CN112190665A (en) | 2020-11-18 | 2020-11-18 | Eye patch for relieving visual fatigue and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112190665A true CN112190665A (en) | 2021-01-08 |
Family
ID=74033127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011294765.2A Pending CN112190665A (en) | 2020-11-18 | 2020-11-18 | Eye patch for relieving visual fatigue and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112190665A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113730272A (en) * | 2021-09-30 | 2021-12-03 | 湖北马应龙八宝生物科技有限公司 | Eye protection patch with efficacy of relieving eye fatigue and preparation method thereof |
CN114272312A (en) * | 2022-02-22 | 2022-04-05 | 郑永记 | Traditional Chinese medicine ointment for improving and conditioning vision and preparation process and using method thereof |
CN114587767A (en) * | 2022-03-30 | 2022-06-07 | 郑州市新视明科技工程有限公司 | Cold compress cover, eye cold compress eye patch and preparation process thereof |
CN114601632A (en) * | 2022-03-02 | 2022-06-10 | 绍兴美琪医疗科技有限公司 | Preparation method of medical cold compress bandage |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101278992A (en) * | 2008-05-30 | 2008-10-08 | 王永近 | Shanbei eye drop |
CN202751496U (en) * | 2012-07-17 | 2013-02-27 | 何竞钟 | Health-care eyeshade |
CN104435763A (en) * | 2014-12-08 | 2015-03-25 | 安龙县东方五官灵制品厂 | Medicine for treating oculopathy |
CN105326887A (en) * | 2015-10-19 | 2016-02-17 | 于林勇 | Ointment for treating myopia and preparation method and usage of ointment for treating myopia |
CN106074959A (en) * | 2016-06-21 | 2016-11-09 | 杨高林 | Black-eyed Chinese medicine composition of a kind of alleviation and preparation method thereof |
CN106421423A (en) * | 2016-11-14 | 2017-02-22 | 郑州百消丹药业有限公司 | Pure traditional Chinese medicine eye pad mainly used for treating myopia and asthenopia and preparation method of pure traditional Chinese medicine eye pad |
CN107510736A (en) * | 2016-06-15 | 2017-12-26 | 陕西新视明医药生物科技有限公司 | The Chinese medicine composition of eye strain is alleviated in a kind of external application |
CN111494348A (en) * | 2020-04-15 | 2020-08-07 | 范春 | Traditional Chinese medicine hydrogel eye mask and preparation method thereof |
-
2020
- 2020-11-18 CN CN202011294765.2A patent/CN112190665A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101278992A (en) * | 2008-05-30 | 2008-10-08 | 王永近 | Shanbei eye drop |
CN202751496U (en) * | 2012-07-17 | 2013-02-27 | 何竞钟 | Health-care eyeshade |
CN104435763A (en) * | 2014-12-08 | 2015-03-25 | 安龙县东方五官灵制品厂 | Medicine for treating oculopathy |
CN105326887A (en) * | 2015-10-19 | 2016-02-17 | 于林勇 | Ointment for treating myopia and preparation method and usage of ointment for treating myopia |
CN107510736A (en) * | 2016-06-15 | 2017-12-26 | 陕西新视明医药生物科技有限公司 | The Chinese medicine composition of eye strain is alleviated in a kind of external application |
CN106074959A (en) * | 2016-06-21 | 2016-11-09 | 杨高林 | Black-eyed Chinese medicine composition of a kind of alleviation and preparation method thereof |
CN106421423A (en) * | 2016-11-14 | 2017-02-22 | 郑州百消丹药业有限公司 | Pure traditional Chinese medicine eye pad mainly used for treating myopia and asthenopia and preparation method of pure traditional Chinese medicine eye pad |
CN111494348A (en) * | 2020-04-15 | 2020-08-07 | 范春 | Traditional Chinese medicine hydrogel eye mask and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
刘落宪: "《中药制药工程原理与设备》", 31 May 2007, 中国中医药出版社 * |
吴国土等: "麝珠明目散对兔离体胸主动脉条及肠管平滑肌的作用", 《福建中医学院学报》 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113730272A (en) * | 2021-09-30 | 2021-12-03 | 湖北马应龙八宝生物科技有限公司 | Eye protection patch with efficacy of relieving eye fatigue and preparation method thereof |
CN113730272B (en) * | 2021-09-30 | 2024-02-09 | 湖北马应龙生物科技有限公司 | Eye-protecting patch with eye fatigue relieving effect and preparation method thereof |
CN114272312A (en) * | 2022-02-22 | 2022-04-05 | 郑永记 | Traditional Chinese medicine ointment for improving and conditioning vision and preparation process and using method thereof |
CN114601632A (en) * | 2022-03-02 | 2022-06-10 | 绍兴美琪医疗科技有限公司 | Preparation method of medical cold compress bandage |
CN114601632B (en) * | 2022-03-02 | 2022-08-30 | 绍兴美琪医疗科技有限公司 | Preparation method of medical cold compress bandage |
CN114587767A (en) * | 2022-03-30 | 2022-06-07 | 郑州市新视明科技工程有限公司 | Cold compress cover, eye cold compress eye patch and preparation process thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112190665A (en) | Eye patch for relieving visual fatigue and preparation method thereof | |
CN104383296B (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method thereof | |
CN106692756A (en) | Polygonatum sibiricum lily ointment and making method thereof | |
CN104758736A (en) | Blood-glucose-reducing traditional Chinese medicine composition and preparation method thereof | |
CN103999986B (en) | A kind of cold tea condensed juice and preparation method thereof | |
CN106387563A (en) | Heat-clearing lung-moistening beverage and preparation method thereof | |
CN113730479A (en) | Composition with health care function and preparation method and application thereof | |
CN112263522B (en) | Composition for relieving and repairing skin and application thereof | |
CN105851390A (en) | Rhizoma gastrodiae, Flos chrysanthemi and Momordica grosvenori tea and making method thereof | |
CN108310298A (en) | It is a kind of that there is the Chinese medicine composition and preparation method for alleviating asthenopia, prevention myopia | |
WO2018099494A1 (en) | Tropaeolum majus effervescent tablet and preparation method therefor | |
CN107260842A (en) | A kind of anti-large intestine cancer treating oral liquid of compound root of herbaceous peony Sculellaria barbata and its preparation technology | |
CN112970992A (en) | Solid beverage suitable for diabetes patients and preparation method thereof | |
CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
CN113663026A (en) | Traditional Chinese medicine eye-protecting liquid and preparation method thereof | |
CN109646521A (en) | A kind of menstruction regulating and pain relieving red date-walnut drink | |
CN111329969A (en) | Traditional Chinese medicine formula for treating cough and asthma and preparation method thereof | |
CN116747286B (en) | A Chinese medicinal composition with weight reducing effect, and its preparation method | |
CN114712458B (en) | Pharmaceutical composition for treating vascular aging of hypertension and preparation method and application thereof | |
WO2020029314A1 (en) | Brewing method for radix notoginseng red rice yeast vinegar | |
CN108740272A (en) | A kind of production method of American Ginseng honey piece | |
CN108653418A (en) | A kind of preparation method of the Colestid traditional Chinese drug inspissation water-bindered pill | |
CN108186874B (en) | A Chinese medicinal composition for treating diabetes | |
CN108379515B (en) | Medicine with angina pectoris treating effect and preparation method thereof | |
CN107753589B (en) | A Chinese medicinal composition for treating diabetes, and its preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |